Osimertinib as a neoadjuvant therapy in resectable EGFR-mutant non-small cell lung cancer: a real-world, multicenter retrospective study

被引：0

作者：

Li, Jialong ^{[1
]}

Wang, Youyu ^{[2
]}

Zhao, Zerui ^{[3
]}

Wang, Sihua ^{[4
]}

Yan, Wanpu ^{[5
]}

Chen, Xiaohui ^{[6
]}

Chen, Tianxiang ^{[7
]}

Li, Pengfei ^{[8
]}

Wang, Sheng ^{[9
]}

Fang, Qiang ^{[1
]}

Peng, Lin ^{[1
]}

Han, Yongtao ^{[1
]}

Tang, Jian ^{[10
]}

Leng, Xuefeng ^{[1
]}

机构：

[1] Univ Elect Sci & Technol China UESTC, Sichuan Canc Hosp & Inst, Sichuan Clin Res Ctr Canc, Sichuan Canc Ctr,Affiliated Canc Hos,Dept Thorac S, Renmin South Rd 55, Chengdu 610042, Peoples R China

[2] Univ Elect Sci & Technol China Uestc, Sichuan Prov Peoples Hosp, Dept Thorac Surg, Chengdu, Peoples R China

[3] Sun Yat Sen Univ, Dept Thorac Surg, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol Southern China,Canc Ctr, Guangzhou, Peoples R China

[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Thorac Surg, Wuhan, Peoples R China

[5] Peking Univ Canc Hosp & Inst, Dept Thorac Surg 1, Key Lab Carcinogenesis & Translat Res, Minist Educ,Peking Univ Sch Oncol, Beijing, Peoples R China

[6] Fujian Canc Hosp, Clin Oncol Sch Fujian Med, Dept Thorac Oncol Surg, Fuzhou, Peoples R China

[7] Shanghai JiaoTong Univ Sch Med, Shanghai Chest Hosp, Dept Oncol Surg, Shanghai, Peoples R China

[8] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Thorac Surg, Shenyang, Peoples R China

[9] Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Thorac Surg, Wuhan, Peoples R China

[10] Nanchang Univ, Affiliated Hosp 1, Dept Thorac Surg, Yongwai Zhengjie 17, Nanchang 330006, Peoples R China

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2024年 / 13卷 / 12期

关键词：

Neoadjuvant; osimertinib; epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC); SYSTEMIC THERAPY; PHASE-II; CHEMORADIATION; SURGERY;

D O I：

10.21037/tlcr-24-541

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), has been authorized for use in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). This study aimed to evaluate the effectiveness and safety of neoadjuvant osimertinib in individuals with resectable locally advanced NSCLC harboring EGFR mutation.Methods: Ten centers located in mainland China took part in a single-arm, real-world, multicenter retrospective study (registration number: ChiCTR2100049954). Enrollment included individuals with lung adenocarcinoma who had EGFR mutations. Following the administration of osimertinib, the patients underwent a surgical procedure for resection. The main endpoint was the objective response rate (ORR). The subsequent endpoint analyzed was the joint assessment of overall survival (OS) and disease-free survival (DFS).Results: From July 31, 2018 to April 28, 2023, a total of 38 individuals were involved and received neoadjuvant osimertinib treatment. The ORR was 60.5% (23/38). Thirty-eight patients underwent surgery, and 36 (94.7%) underwent successful R0 resection. Out of 38 patients, sixteen (42.1%) experienced adverse events (AEs) due to treatment in the neoadjuvant phase, with none of them reaching grade 3. Skin irritation [14 (36.8%)], stomach upset [5 (13.2%)], mouth sores [1 (2.6%)] and increased liver enzyme levels [1 (2.6%)] were the common AEs of treatment. The follow-up period lasted an average of 24.9 months. The 1-year OS rate is 94.2%, while the 2-year OS rate is 89.2%. The 1-year DFS rate is 87.9%, and the 2-year DFS rate remains at 87.9% Conclusions: In the actual clinical setting, osimertinib displays encouraging possibilities as a neoadjuvant therapy for individuals with operable EGFR-mutated NSCLC, exhibiting adequate efficacy and an acceptable safety record. The phase III clinical trial of NeoADAURA is expected to provide further efficacy and safety results

引用

页码：3344 / 3351

页数：8

共 27 条

[1] Bray F, Laversanne M, Sung H, Et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 74, pp. 229-263, (2024)
[2] Han B, Zheng R, Zeng H, Et al., Cancer incidence and mortality in China, 2022, J Natl Cancer Cent, 4, pp. 47-53, (2024)
[3] Asamura H, Chansky K, Crowley J, Et al., The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer, J Thorac Oncol, 10, pp. 1675-1684, (2015)
[4] Muthusamy B, Patil PD, Pennell NA., Perioperative Systemic Therapy for Resectable Non-Small Cell Lung Cancer, J Natl Compr Canc Netw, 20, pp. 953-961, (2022)
[5] Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data, Lancet, 383, pp. 1561-1571, (2014)
[6] MacLean M, Luo X, Wang S, Et al., Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database, Oncotarget, 9, pp. 24470-24479, (2018)
[7] Yu Z, Xu F, Zou J., Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis, Eur J Clin Pharmacol, 80, pp. 505-517, (2024)
[8] Piper-Vallillo A, Mak R, Lanuti M, Et al., FP01.05 the ASCENT trial: a phase II study of neoadjuvant/adjuvant Afatinib, Chemoradiation +/- Surgery for Stage III EGFR-Mutant NSCLC, J Thorac Oncol, 16, (2021)
[9] Cheng Y, He Y, Li W, Et al., Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study, Target Oncol, 16, pp. 165-176, (2021)
[10] Detterbeck FC, Boffa DJ, Kim AW, Et al., The Eighth Edition Lung Cancer Stage Classification, Chest, 151, pp. 193-203, (2017)

← 1 2 3 →